An immunosuppressive drug that blocks the inflammatory protein IL-6. This may improve symptoms caused by inflammationA process of the immune system that involves chemicals released by immune cells (i.e. white blood cells) inducing localized heat, swelling, redness, and pain to an area that occurs when tissue becomes damaged or infected from a pathogen, and usually results in the desctruction and removal of the pathogen and/or healing to the tissue. In the case of myelin oligodendrocyte glycoprotein antibody disease (MOGAD), inflammation is the result of the incorrect targeting of the myelin oligodendrocyte glycoprotein (MOG) by the immune system, resulting in damage to myelin sheaths.. The common brand for this drug is Actemra. For myelin oligodendrocyte glycoprotein antibody disease (MOGAD)Often referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease , this medication is used to suppress the immune system to reduce disease activity. May be given intraveneously or by subcutaneousA method of administering medication by injection under the skin. injection.
Related Posts
The MOG Project Awards 2025 Research Grants
The MOG Project’s Research for Rare program has awarded our 2025 MOGADOften referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease global research grants: the Apollo Grant and the Accelerator Grant. These grants are
Eliza’s Story: Weaving Emotional Support into the Fabric of Rare Disease Advocacy
Hello everyone, My name is Eliza, and at the age of 34, I was diagnosed with MOGADOften referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease – a disease I had never heard of
My 21 year old son has been diagnosed with MOGAD and my question is how do you get approval for Actemra? Our insurance has denied a bio similar drug already.